RxDoctor Payments Data

Charla Watson

Family · Hamilton, ALNPI 1659770527

Payments from drug & device makers

$778in general payments, 2019–2025

Across 57 payments — averaging $13.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$431
  • Lilly USA, LLC$118
  • Amgen$62
  • AstraZeneca$58
  • GSK$28
  • Novo Nordisk$21
  • plus $60 from 3 others

What the payments were for

  • Food & beverage$76798%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$778 in reported general payments places this provider in the 60th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$89,554
Medicare patients
269
Services billed
1,975

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide77$74,264
TrulicityDulaglutide69$71,985
Trelegy ElliptaFluticasone/Umeclidin/Vilanter76$55,775
MounjaroTirzepatide49$50,457
FarxigaDapagliflozin Propanediol38$40,403
LinzessLinaclotide45$25,430
EliquisApixaban31$20,049
MyrbetriqMirabegron44$18,331
Breo ElliptaFluticasone/Vilanterol42$17,022
RybelsusSemaglutide18$15,776
XareltoRivaroxaban28$14,661
JanuviaSitagliptin Phosphate22$11,132
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$9,575
Fiasp FlextouchInsulin Aspart (Niacinamide)11$7,411
Fluticasone Propionate297$5,086

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$118$122,442118 claims
Novo NordiskOzempic, Rybelsus$21$90,03995 claims
GSKTrelegy Ellipta, Breo Ellipta$28$72,797118 claims
AstraZenecaFarxiga, Nexium$58$44,01151 claims
AbbVieLinzess, Synthroid$431$26,99761 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,415 family providers in Alabama.

Other family in Hamilton

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →